A Mage3/Heat Shock Protein70 DNA vaccine induces both innate and adaptive immune responses for the antitumor activity

Vaccine

Volumn 28, Issue 2, 2009, Pages 561-570

  Wang, Lifeng ^a   Rollins, Lisa ^b,c   Gu, Qinlong ^b   Chen, Si Yi ^a,b   Huang, Xue F ^a,b,c  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b CENTER FOR CELL AND GENE THERAPY   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Antitumor activity; DNA vaccine; Heat shock protein; Mage3

Indexed keywords

CANCER TESTIS ANTIGEN; DNA VACCINE; GAMMA INTERFERON; HEAT SHOCK PROTEIN 70; HYBRID PROTEIN; MELANOMA ANTIGEN 3; RANTES; RECOMBINANT PROTEIN;

ADAPTIVE IMMUNITY; AMINO TERMINAL SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CARBOXY TERMINAL SEQUENCE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOTOXICITY; DNA IMMUNIZATION; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; INNATE IMMUNITY; INOCULATION; MOUSE; NATURAL KILLER CELL; NONHUMAN; PLASMID; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

ADAPTIVE IMMUNITY; ANIMALS; ANTIGENS, NEOPLASM; CANCER VACCINES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENETIC VECTORS; HSP70 HEAT-SHOCK PROTEINS; IMMUNITY, INNATE; IMMUNOPRECIPITATION; MICE; MICE, KNOCKOUT; NEOPLASM PROTEINS; VACCINES, DNA;

EID: 70649111280     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.09.119     Document Type: Article

References (50)

1. Scanlan M.J., Gure A.O., Jungbluth A.A., Old L.J., and Chen Y.T. Cancer/testis antigens: an expanding family of targets for cancer immunotherapy. Immunol Rev 188 (2002) 22-32
2. Van der Bruggen P., van der Bruggen P., Traversari C., Chomez P., Lurquin C., De Plaen E., et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254 5038 (1991) 1643-1647
3. Traversari C., van der Bruggen P., Van den Eynde B., Hainaut P., Lemoine C., Ohta N., et al. Transfection and expression of a gene coding for a human melanoma antigen recognized by autologous cytolytic T lymphocytes. Immunogenetics 35 3 (1992) 145-152
4. Sahin U., Türeci O., Schmitt H., Cochlovius B., Johannes T., Schmits R., et al. Human neoplasms elicit multiple specific immune responses in the autologous host. Proc Natl Acad Sci USA 92 25 (1995) 11810-11813
5. Lethe B., Lucas S., Michaux L., De Smet C., Godelaine D., Serrano A., et al. LAGE-1, a new gene with tumor specificity. Int J Cancer 76 6 (1998) 903-908
6. Zendman A.J., Cornelissen I.M., Weidle U.H., Ruiter D.J., and van Muijen G.N. CTp11, a novel member of the family of human cancer/testis antigens. Cancer Res 59 24 (1999) 6223-6229
7. De Wit N., Weidle U.H., Ruitter D.J., and van Muijen G.N.P. Expression profiling of MMA-1 and splice variant MMA-1B: new cancer/testis antigens identified in human melanoma. Int J Cancer 98 4 (2002) 547-553
8. Van den Eynde B.J., and van der Bruggen P. T cell defined tumor antigens. Curr Opin Immunol 9 5 (1997) 684-693
9. Van der Bruggen P., Bastin J., Gajewski T., Coulie P.G., Boel P., De Smet C., et al. A peptide encoded by human gene MAGE-3 and presented by HLA-A2 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE-3. Eur J Immunol 24 12 (1994) 3038-3043
10. Tanaka F., Fujie T., Tahara K., Mori M., Takesako K., Sette A., et al. Induction of antitumor cytotoxic T lymphocytes with a MAGE-3-encoded synthetic peptide presented by human leukocytes antigen-A24. Cancer Res 57 20 (1997) 4465-4468
11. Chaux P., Vantomme V., Stroobant V., Thielemans K., Corthals J., Luiten R., et al. Identification of MAGE-3 epitopes presented by HLA-DR molecules to CD4(+) T lymphocytes. J Exp Med 189 5 (1999) 767-778
12. Manici S., Sturniolo T., Imro M.A., Hammer J., Sinigaglia F., Noppen C., et al. Melanoma cells present a MAGE-3 epitope to CD4(+) cytotoxic T cells in association with histocompatibility leukocyte antigen DR11. J Exp Med 189 5 (1999) 871-876
13. Weber J.S., Hua F.L., Spears L., Marty V., Kuniyoshi C., and Celis E. A phase I trial of an HLA-A1 restricted MAGE-3 epitope peptide with incomplete Freund's adjuvant in patients with resected high-risk melanoma. J Immunother 22 5 (1999) 431-440
14. Nestle F.O., Alijagic S., Gilliet M., Sun Y., Grabbe S., Dummer R., et al. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 4 3 (1998) 328-332
15. Reynolds S.R., Oratz R., Shapiro R.L., Hao P., Yun Z., Fotino M., et al. Stimulation of CD8+ T cell responses to MAGE-3 and Melan A/MART-1 by immunization to a polyvalent melanoma vaccine. Int J Cancer 72 6 (1997) 972-976
16. Lindquist S. The heat-shock response. Annu Rev Biochem 55 (1986) 1151-1191
17. Tamura Y., Peng P., Liu K., Daou M., and Srivastava P.K. Immunotherapy of tumors with autologous tumor-derived heat shock protein preparations. Science 278 5335 (1997) 117-120
18. Srivastava P.K. Immunotherapy of human cancer: lessons from mice. Nat Immunol 1 5 (2000) 363-366
19. Srivastava P. Interaction of heat shock proteins with peptides and antigen presenting cells: chaperoning of the innate and adaptive immune responses. Annu Rev Immunol 20 (2002) 395-425
20. Binder R.J. Heat-shock protein-based vaccines for cancer and infectious disease. Expert Rev Vaccines 7 3 (2008) 383-393
21. Hauser H., Shen L., Gu Q.L., Krueger S., and Chen S.Y. Secretory heat-shock protein as a dendritic cell-targeting molecule: a new strategy to enhance the potency of genetic vaccines. Gene Ther 11 11 (2004) 924-932
22. Hsu K.F., Hung C.F., Cheng W.F., He L., Slater L.A., Ling M., et al. Enhancement of suicidal DNA vaccine potency by linking Mycobacterium tuberculosis heat shock protein 70 to an antigen. Gene Ther 8 5 (2001) 376-383
23. Suzue K., and Young R.A. Adjuvant-free hsp70 fusion protein system elicits humoral and cellular immune responses to HIV-1 p24. J Immunol 156 2 (1996) 873-879
24. Suzue K., Zhou X., Eisen H.N., and Young R.A. Heat shock fusion proteins as vehicles for antigen delivery into the major histocompatibility complex class I presentation pathway. Proc Natl Acad Sci USA 94 24 (1997) 13146-13151
25. Ciupitu A.M., Petersson M., Kono K., Charo J., and Kiessling R. Immunization with heat shock protein 70 from methylcholanthrene-induced sarcomas induces tumor protection correlating with in vitro T cell responses. Cancer Immunol Immunother 51 3 (2002) 163-170
26. Janetzki S., Palla D., Rosenhauer V., Lochs H., Lewis J.J., and Srivastava P.K. Immunization of cancer patients with autologous cancer-derived heat shock protein gp96 preparations: a pilot study. Int J Cancer 88 2 (2000) 232-238
27. Ma J.H., Sui Y.F., Ye J., Huang Y.Y., Li Z.S., Chen G.S., et al. Heat shock protein 70/MAGE-3 fusion protein vaccine can enhance cellular and humoral immune responses to MAGE-3 in vivo. Cancer Immunol Immunother 54 9 (2005) 907-914
28. You Z., Hester J., Rollins L., Spagnoli G.C., van der Bruggen P., and Chen S.Y. A retrogen strategy for presentation of an intracellular tumor antigen as an exogenous antigen by dendritic cells induces potent antitumor T helper and CTL responses. Cancer Res 61 1 (2001) 197-205
29. Kocher T., Schultz-Thater E., Gudat F., Schaefer C., Casorati G., Juretic A., et al. Identification and intracellular location of MAGE-3 gene product. Cancer Res 55 11 (1995) 2236-2239
30. Inaba K., Steinman R.M., Pack M.W., Aya H., Inaba M., Sudo T., et al. Identification of proliferating dendritic cell precursors in mouse blood. J Exp Med 175 5 (1992) 1157-1167
31. Rosenzwajg M., Camus S., Guigon M., and Gluckman J.C. The influence of interleukin (IL)-4, IL-13, and Flt3 ligand on human dendritic cell differentiation from cord blood CD34+ progenitor cells. Exp Hematol 26 1 (1998) 63-72
32. Rougier N., Schmitt D., and Vincent C. IL-4 addition during differentiation of CD34 progenitors delays maturation of dendritic cells while promoting their survival. Eur J Cell Biol 75 3 (1998) 287-293
33. Zhang B., Yamamura T., Kondo T., Fujiwara M., and Tabira T. Regulation of experimental autoimmune encephalomyelitis by natural killer (NK) cells. J Exp Med 186 10 (1997) 1677-1687
34. Wang R.F., and Wang H.Y. Enhancement of antitumor immunity by prolonging antigen presentation on dendritic cells. Nat Biotechnol 20 2 (2002) 149-154
35. Srivastava P. Roles of heat-shock proteins in innate and adaptive immunity. Nat Rev Immunol 2 3 (2002) 185-194
36. Lin K.Y., Guarnieri F.G., Staveley-O'Carroll K.F., Levitsky H.I., August J.T., Pardoll D.M., et al. Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res 56 1 (1996) 21-26
37. Beláková J., Horynová M., Krupka M., Weigl E., and Raska M. DNA vaccines: are they still just a powerful tool for the future?. Arch Immunol Ther Exp (Warsz) 55 6 (2007) 387-398
38. Multhoff G. Heat shock protein 70 (Hsp70): membrane location, export and immunological relevance. Methods 43 3 (2007) 229-237
39. Strbo N., and Podack E.R. Secreted heat shock protein gp96-Ig: an innovative vaccine approach. Am J Reprod Immunol 59 5 (2008) 407-416
40. Ullrich E., Ménard C., Flament C., Terme M., Mignot G., Bonmort M., et al. Dendritic cells and innate defense against tumor cells. Cytokine Growth Factor Rev 19 1 (2008) 79-92
41. Trinchieri G. Biology of natural killer cells. Adv Immunol 47 (1989) 187
42. Bloom B.R. Natural killers to rescue immune surveillance?. Nature 300 5889 (1982) 214-215
43. Bauer S., Groh V., Wu J., Steinle A., Phillips J.H., Lanier L.L., et al. Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science 285 5428 (1999) 727-729
44. Vivier E., Tomasello E., Baratin M., Walzer T., and Ugolini S. Functions of natural killer cells. Nat Immunol 9 5 (2008) 503-510
45. Nicchitta C.V. Re-evaluating the role of heat-shock protein-peptide interactions in tumour immunity. Nat Rev Immunol 3 5 (2003) 427-432
46. Van Pel A., De Plaen E., Duffour M.T., Warnier G., Uyttenhove C., Perricaudet M., et al. Induction of cytolytic T lymphocytes by immunization of mice with an adenovirus containing a mouse homolog of the human MAGE-A genes. Cancer Immunol Immunother 49 11 (2001) 593-602
47. Bae M.Y., Cho N.H., and Seong S.Y. Protective anti-tumour immune responses by murine dendritic cells pulsed with recombinant Tat-carcinoembryonic antigen derived from Escherichia coli. Clin Exp Immunol 157 1 (2009) 128-138
48. Gabrilovich D.I., and Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 9 3 (2009) 162-174
49. Sica A., and Bronte V. Altered macrophage differentiation and immune dysfunction in tumor development. J Clin Invest 117 5 (2007) 1155-1166
50. Curotto de Lafaille M.A., and Lafaille J.J. Natural and adaptive foxp3+ regulatory T cells: more of the same or a division of labor?. Immunity 30 5 (2009) 626-635